Payment overview · 2025
General Payments
$523.49
24 reported records · 10 companies
Healthcare provider profile · identity verified
Tedla Anbessie, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ALEXANDRIA, VA · NPI 1972590743
Verified facts
What the public records show
CMS Open Payments records show Tedla Anbessie, MD received $523.49 in general payments during 2025 across 24 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $143.07 | 27.3% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $126.92 | 24.2% | 6 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $63.51 | 12.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.63 | 7.4% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $31.71 | 6.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $30.91 | 5.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $28.18 | 5.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.18 | 4.4% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $22.10 | 4.2% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $15.28 | 2.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $523.49 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $108.11 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $108.11 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $95.67 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.73 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $31.71 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $28.18 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $27.93 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.47 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.96 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $15.28 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $14.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 69 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
69 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
56 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
220 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 146 |
| Amlodipine Besylate | Amlodipine Besylate | 400 | 111 |
| Levothyroxine Sodium | Levothyroxine Sodium | 280 | 46 |
| Furosemide | Furosemide | 268 | 57 |
| Lisinopril | Lisinopril | 226 | 54 |
| Eliquis | Apixaban | 220 | 41 |
| Metformin Hcl | Metformin Hcl | 206 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 171 | 60 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 36 |
| Tamsulosin Hcl | Tamsulosin Hcl | 162 | 44 |
| Gabapentin | Gabapentin | 147 | 67 |
| Losartan Potassium | Losartan Potassium | 142 | 48 |
| Carvedilol | Carvedilol | 122 | 40 |
| Trazodone Hcl | Trazodone Hcl | 112 | 38 |
| Omeprazole | Omeprazole | 104 | 37 |
| Mirtazapine | Mirtazapine | 98 | 29 |
| Simvastatin | Simvastatin | 95 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 89 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 89 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 89 | 33 |
| Trulicity | Dulaglutide | 88 | 17 |
| Famotidine | Famotidine | 87 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 28 |
| Allopurinol | Allopurinol | 84 | 18 |
| Finasteride | Finasteride | 84 | 15 |
| Jardiance | Empagliflozin | 81 | 15 |
| Xarelto | Rivaroxaban | 79 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 71 | 18 |
| Potassium Chloride | Potassium Chloride | 70 | 18 |
| Farxiga | Dapagliflozin Propanediol | 69 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 22 |
| Sertraline Hcl | Sertraline Hcl | 65 | 14 |
| Alendronate Sodium | Alendronate Sodium | 64 | 17 |
| Atenolol | Atenolol | 64 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 64 | 19 |
| Entresto | Sacubitril/Valsartan | 62 | suppressed |
| Ozempic | Semaglutide | 56 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 55 | 17 |
| Levetiracetam | Levetiracetam | 54 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 53 | 16 |
| Baclofen | Baclofen | 52 | suppressed |
| Memantine Hcl | Memantine Hcl | 52 | 13 |
| Lactulose | Lactulose | 51 | suppressed |
| Celecoxib | Celecoxib | 49 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 49 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 47 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 44 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 40 | 11 |
| Spironolactone | Spironolactone | 38 | 15 |
| Cefdinir | Cefdinir | 36 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 22 |
| Methylprednisolone | Methylprednisolone | 35 | 30 |
| Prednisone | Prednisone | 34 | 28 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | 14 |
| Meloxicam | Meloxicam | 33 | 19 |
| Glipizide | Glipizide | 32 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | 20 |
| Glimepiride | Glimepiride | 31 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | 12 |
| Sucralfate | Sucralfate | 31 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 29 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Xifaxan | Rifaximin | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Acetazolamide | Acetazolamide | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 12 |
| Azithromycin | Azithromycin | 24 | 21 |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | 11 |
| Valsartan | Valsartan | 24 | 11 |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Latanoprost | Latanoprost | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 15 |
| Tramadol Hcl | Tramadol Hcl | 18 | 14 |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | 11 |
| Pregabalin | Pregabalin | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Glyburide-Metformin Hcl | Glyburide/Metformin Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Dextrose In Water | Dextrose 5 % In Water | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $523.49 · 24 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, EVENITY, FARXIGA, NURTEC ODT, OTEZLA, PAXLOVID, QULIPTA, REPATHA, REXULTI, The Cologuard Plus Collection Kit, WATCHMAN Access System, YUPELRI | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error